Navigation Links
Intercell AG Announces Q1 2011 Results and Updates on R&D Progress
Date:5/10/2011

VIENNA, May 10, 2011 /PRNewswire/ -- Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its financial results for Q1 and presented an update on the Company's development programs.

Financial Results

  • Year-on-year revenue growth of 19.7% driven by strong IXIARO®/JESPECT® sales revenues
  • Restructuring process progressing successfully – operating loss reduced by 33.1%
  • Higher sales and reduced spending lead to reduced net loss of EUR 11.3m
  • Cash position of EUR 87.7m at quarter-end
  • Unchanged net loss expectation of EUR 3
    40m for full year 2011

  • Key Financial Figures EUR in thousands

    3 months ended
    March 31,Year ended Dec. 31,201120102010Revenues

    5,6924,75634,215Net loss

    (11,257)(14,702)(255,182)Net operating cash flow

    (23,453)(15,468)(65,120)Cash and marketable securities, end of period

    87,697158,21686,182IXIARO®/JESPECT® Revenues from IXIARO®/JESPECT® product sales increased from EUR 0,4m in Q1 2010 to EUR 3.3m in Q1 2011. This excellent result in the usually weakest quarter of the year - due to travel seasonality - reflects the positive trend of increasing sales of IXIARO®/JESPECT® a already seen in 2010 in key travel markets and to U.S. military.

    Intercell expects a growth of sales to the U.S. military in 2011 due to higher vaccination rates and the finally expired stock of no longer manufactured JE-Vax®.

    Intercell continues to expand the global availability of IXIARO® by increasing the number of regulatory approvals and subsequent launches in various global markets. Furthermore it is planning to launch the product with its partner Novartis in additional European countries as well as Hong Kong and Singapore as the first Asian territories during 2011.

    The U.S. authorities recently confirmed to Intercell that the first postmarketing safety evaluation of IXIARO® concluded that no new safety concerns were identified and no labeling changes are requested at this time.

    Progress in Intercell's growing nosocomial vaccine franchise

  • Next steps defined for Pseudomonas vaccine candidate: Agreement with Novartis to advance investigational Pseudomonas vaccine into confirmatory clinical efficacy trial in ventilated ICU patients
  • Update on Staphylococcus aureus vaccine candidate: Study not futile - pre-specified futility criteria not met in Phase II/III trial (cardiothoracic surgery) - Independent DMC recommended suspension of enrollment pending further analyses of the benefit/risk profile - further update expected after completion of analyses.
  • Clostridium difficile vaccine candidate - Phase I trial progressing according to plan - First study results expected in 2011

  • Progress in Pandemic Influenza Vaccine Enhancement Patch (VEP) – Intercell and GSK maintain commitment on strategic patch collaboration

    IC31® adjuvant Novartis has initiated a Phase I clinical trial, combining an undisclosed vaccine candidate with Intercell's IC31® adjuvant. Under a Strategic Alliance Agreement signed in 2007, Novartis received a non exclusive license for the use of IC31® in selected new vaccines.

    Corporate

  • Thomas Lingelbach appointed new CEO of Intercell, effective May 10, 2011; Gerd Zettlmeissl resigns from the management board as of today

  • The full report can be downloaded at http://www.intercell.com/main/forinvestors/downloads/quarterly-reports/  

    This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business, including words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," or similar words. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


    '/>"/>

    SOURCE Intercell AG
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
    2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
    3. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
    4. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
    5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
    6. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
    7. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
    8. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
    9. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
    10. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
    11. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
    (Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
    (Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
    Breaking Medicine Technology:
    (Date:9/24/2017)... ... September 25, 2017 , ... The Venetian on Grace ... on October 1st. And, throughout the month of October, the resort will be ... Hurricane Irma and Maria have passed and damage to the Venetian was very minimal ...
    (Date:9/24/2017)... ... ... “The Messiah 8 with the 3rd Anti Christ”: a forceful and dynamic narrative ... 3rd Anti Christ” is the creation of published author, Albert Velazquez. , ... life,” Velazquez states, “I always come to the same conclusion: God loves working in ...
    (Date:9/23/2017)... ... 23, 2017 , ... A September 5 article ... director of Chicago’s Center for Lifestyle Medicine at Northwestern Medicine. While explaining Dr. ... that the center routinely recommends weight loss surgeries for patients who meet the ...
    (Date:9/22/2017)... ... September 22, 2017 , ... On Sunday, September 24, hundreds will gather ... Florence Joyner, still considered the fastest woman of all time. Flo Jo passed ... Joyner, will sing the National Anthem. Mary was a contestant on the 2012 ...
    (Date:9/22/2017)... ... September 22, 2017 , ... After a long health ... a new lease on life with assistance from CreditAssociates. CreditAssociates provides debt relief ... with unsecured debt. The senior is one of the satisfied clients who expressed ...
    Breaking Medicine News(10 mins):